Diffuse Scleroderma clinical trials at UCLA
7 in progress, 3 open to eligible people
Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
open to eligible people ages 18 years and up
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Los Angeles 5368361, California 5332921 and other locations
BMS-986278 in Participants With Progressive Pulmonary Fibrosis
open to eligible people ages 21 years and up
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Los Angeles 5368361, California 5332921 and other locations
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
open to eligible people ages 18-70
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Los Angeles 5368361, California 5332921 and other locations
Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Los Angeles 5368361, California 5332921 and other locations
Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
Sorry, currently not accepting new patients, but might later
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).
Los Angeles 5368361, California 5332921 and other locations
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Sorry, in progress, not accepting new patients
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Los Angeles 5368361, California 5332921 and other locations
Platform Clinical Study for Conquering Scleroderma
Sorry, not currently recruiting here
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Diffuse Scleroderma research studies include Suzanne Kafaja, MD Elizabeth R. Volkmann, MD, MS John A. Belperio, MD.
Last updated: